Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

NCT06975644 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Triple-Negative Breast Cancer (TNBC)
Neoadjuvant Chemotherapy
Chemotherapy Effects

Interventions

DRUG: nab-paclitaxel, carboplatin, and bemotuzumab
DRUG: epirubicin, cyclophosphamide, and bemotuzumab

Sponsor

Zhejiang Provincial People's Hospital